Lung cancer treatment is changing, thanks to research in prevention, early detection and treatment. Recent advances include new ways to operate on lung cancer, improvements in radiation techniques and the approval of new therapies that target a specific feature of the cancer and activate the immune system against the cancer. These are some of the current major areas of research

in lung cancer:

Targeted Therapies

The area of personalized medicine in cancer and the role that targeted therapies play is one of the most active areas of research in lung cancer. While several targeted therapies have already been approved for use in lung cancer (see Targeted Therapies), many more have been identified as possible treatments and are being tested in clinical trials.

  • Necitumumab is designed to target the EGFR mutation and is showing promise in the treatment of advanced squamous cell carcinoma, a type of NSCLC.
  • Dabrafenib (Tafinlar) is a kinase inhibitor, currently approved for the treatment of melanoma that contains the BRAF V600E mutation and cannot be removed by surgery or has spread.
  • Cetuximab (Erbitux) is a monoclonal antibody and an epidermal growth factor receptor (EGFR) inhibitor.

Unfortunately, cancer always finds a way to get around targeted therapies and they eventually stop working. Research efforts are underway to find new treatments to overcome this “resistance.” Two drugs in particular show promise and are expected to be FDA approved in 2015, AZ-9291 and Rociletinib. Both work against EGFR to overcome the most common way that cancer develops resistance to those targeted therapies.


Immunotherapy is another promising area of lung cancer research. Immunotherapies increase the body’s natural defenses to attack cancer, to fight and target disease and to improve and restore function to the immune system. Several approaches being studied in lung cancer:

Checkpoint inhibitors

The immune system is kept under control by “checkpoints.” Cancer cells can fool the checkpoints so that it can do what it wants without being slowed down or stopped. Checkpoint inhibitors work to fix the problem so that the immune system can work against the cancer. The fix on the checkpoint may turn it on to work against the cancer or it may turn off the checkpoint so the cancer can’t get through without being caught.  (see Immunotherapies)

Monoclonal antibodies

Antibodies are proteins produced in blood to fight toxins or foreign substances in the body. To treat cancer, the cancer cells that grow and spread out of control are foreign substances to target. Monoclonal antibodies (mAbs) are man-made and designed to work with those the body creates naturally to help the immune system fight and shut down the growth of the cancer. They can be used alone or with other drugs to target defects in the cancer cells or to make the cancer cells more receptive to the body’s immune system. Monoclonal antibodies can also carry other drugs or substances directly to the cancer.


There are two types of cancer vaccines: prophylactic vaccines which prevent cancer and therapeutic vaccines which are used to treat cancer or to prevent recurrence. In lung cancer, prophylactic vaccines have not been a focus of research. Trials involving vaccines to prevent lung cancer from coming back have yet to show they are effective, however a wide variety of approaches to help make the immune system work against lung cancer are being tested. Some include activating the immune system against particular proteins found on cancer cells. Other approaches target one or more specific antigens, the toxins or other substances that cause the immune system to act in the body.

Vaccine updates: In March 2014, Mage A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) failed to significantly extend disease-free survival compared to placebo, in either the overall MAGE-A3 (a specific tumour antigen) positive population or in MAGE-A3-positive patients who did not receive chemotherapy. In February 2013, the Lucanix trial was closed because it was not on track to meet its primary endpoint and in December 2012, the Stimuvax trial was closed because it did not meet its primary endpoint. Vaccines for lung cancer continue to be tested in clinical trials.

*FDA Breakthrough Therapy designation was enacted in 2012 and includes all the features of Fast Track designation (given to fast track drugs that may treat serious or life-threatening illnesses, address an unmet medical need or make a positive advancement in safety or effectiveness over existing drugs) but includes more intensive guidance from the FDA on the drug’s clinical development program.


While much research is focusing on developing novel approaches to lung cancer treatment in the form of targeted therapies and immunotherapies, research is ongoing into new chemotherapies or improvements on existing chemotherapies.

Maintenance Therapies

While several drugs have been approved for use or are commonly used as maintenance therapy, oncologists do not fully agree on whether it is always the best option. Research is continuing to test maintenance therapies in an effort to better identify patients who will benefit from them.


While important research is going on in the treatment and diagnosis of lung cancer, another area of research is in chemoprevention, or the use of substances to prevent lung cancer from developing. This research has many challenges, and so far researchers have had mixed results come from their studies. Current research is focusing on drugs that have been approved for treatment in other conditions but that potentially decrease risk of lung cancer.

Early Detection

Access to quality screening for those at high risk for lung cancer is becoming common place all over the United States. You can find information on screening here and help finding a center of excellence near you here. Several other approaches are being explored to detect and screen for lung cancer, including blood tests, breath tests, sputum cytology and cell sampling from airway via bronchoscopy. While these are still in the research phase, these kinds of tests may one day be widely available.